Royal Bank of Canada’s Scinai Immunotherapeutics SCNI Stock Holding History

Royal Bank of Canada’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+82	New	+$403	﹤0.01%	7749
2024 Q2	–	Hold	0	–	–	–	7476
2024 Q1	–	Hold	0	–	–	–	7521
2023 Q4	–	Hold	0	–	–	–	7524
2023 Q3	–	Hold	0	–	–	–	7518
2023 Q2	–	Hold	0	–	–	–	7614
2023 Q1	–	Sell	-3	Closed	-$740	–	7418
2022 Q4	$1K	Hold	3	–	–	﹤0.01%	7076
2022 Q3	$2K	Hold	3	–	–	﹤0.01%	7062
2022 Q2	$3K	Hold	3	–	–	﹤0.01%	6852
2022 Q1	$4K	Hold	3	–	–	﹤0.01%	7335
2021 Q4	$6K	Hold	3	–	–	﹤0.01%	7191
2021 Q3	$6K	Hold	3	–	–	﹤0.01%	7092
2021 Q2	$7K	Hold	3	–	–	﹤0.01%	6984
2021 Q1	$10K	Hold	3	–	–	﹤0.01%	6816
2020 Q4	$7K	Sell	3 -1	-25%	-$12.1K	﹤0.01%	6541
2020 Q3	$141K	Buy	4 +1	+33%	+$38.4K	﹤0.01%	4769
2020 Q2	$78K	Hold	3	–	–	﹤0.01%	5003
2020 Q1	$27K	Buy	3 +2	+200%	+$17.7K	﹤0.01%	5424
2019 Q4	$8K	Hold	1	–	–	﹤0.01%	6227
2019 Q3	$5K	Hold	1	–	–	﹤0.01%	6039
2019 Q2	$5K	Hold	1	–	–	﹤0.01%	6322
2019 Q1	$5K	Hold	1	–	–	﹤0.01%	6272
2018 Q4	$4K	Hold	1	–	–	﹤0.01%	6248
2018 Q3	$5K	Hold	1	–	–	﹤0.01%	6275
2018 Q2	$6K	Hold	1	–	–	﹤0.01%	5994
2018 Q1	$5K	Buy	+1	New	+$6.24K	﹤0.01%	5934

Other funds holding SCNI

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada's SCNI Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in Scinai Immunotherapeutics (SCNI) in Q2 2026: 82 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #7749 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in SCNI as recently as Q4 2022.

Royal Bank of Canada first reported a position in SCNI in Q1 2018 and has held it in 21 quarters since. The position peaked at $141K in Q3 2020. 11 funds tracked by Wall St. Rank hold SCNI as of Q2 2026.

Royal Bank of Canada held 82 shares of Scinai Immunotherapeutics worth $0 as of Q2 2026.
Scinai Immunotherapeutics was a new Royal Bank of Canada position in Q2 2026.
Scinai Immunotherapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #7749 holding.
Royal Bank of Canada first reported a position in Scinai Immunotherapeutics in Q1 2018 and has held it in 21 quarters since.
Royal Bank of Canada's Scinai Immunotherapeutics position peaked at $141K in Q3 2020.
11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.